Concomitant drugs with exposure to contrast media

Kidney International

Volumn 69, Issue SUPPL. 100, 2006, Pages

  Erley, C ^a  

^a ST JOSEPH KRANKENHAUS   (Germany)

Author keywords

Concomitant drugs; Contrast media nephrotoxicity; NSAIDs; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIHYPERTENSIVE AGENT; CASPOFUNGIN; CONTRAST MEDIUM; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; CYSTATIN C; DALFOPRISTIN PLUS QUINUPRISTIN; DIPYRIDAMOLE; DIURETIC AGENT; DOPAMINE; FENOLDOPAM; GEMFIBROZIL; IODINATED CONTRAST MEDIUM; LINEZOLID; MANNITOL; METFORMIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE; STATINE DERIVATIVE; TACROLIMUS; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGING; ANALGESIC NEPHROPATHY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMORBIDITY; CONTRAST INDUCED NEPHROPATHY; DRUG EXPOSURE; DRUG FATALITY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERKALEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LACTIC ACIDOSIS; MEASUREMENT; NEPHROTOXICITY; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SENSITIVITY AND SPECIFICITY;

EID: 33646162661     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000370     Document Type: Article

References (60)

1. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
2. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
3. Freeman RV, O'Donnell M, Share D et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073.
4. Cederholm C, Almen T, Bergqvist D et al. Acute renal failure in rats. Interaction between contrast media and temporary renal arterial occlusion. Acta Radiol 1989; 30: 321-326.
5. Deray G, Dubois M, Martinez F et al. Renal effects of radiocontrast agents in rats: a new model of acute renal failure. Am J Nephrol 1990; 10: 507-513.
6. Osswald H, Schmidt HJ, Kemper R. Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation. Pflugers Arch 1977; 371: 45-49.
7. Osswald H, Schmitz HJ, Heidenreich O. Adenosine response of the rat kidney after saline loading, sodium restriction and hemorrhagia. Pflugers Arch 1975; 357: 323-333.
8. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 1997; 204: 297-312.
9. Caldicott WJ, Hollenberg NK, Abrams HL. Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970; 5: 539-547.
10. Workman RJ, Shaff MI, Jackson RV et al. Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol 1983; 18: 160-166.
11. Larson TS, Hudson K, Mertz JI et al. Renal vasoconstrictive response to contrast medium. The role of sodium balance and the renin-angiotensin system. J Lab Clin Med 1983; 101: 385-391.
12. Heyman SN, Clark BA, Kaiser N et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992; 3: 58-65.
13. Oldroyd SD, Haylor JL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 1995; 196: 661-665.
14. Russo D, Minutolo R, Cianciaruso B et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-1458.
15. Haas JA, Osswald H. Adenosine induced fall in glomerular capillary pressure: effect of ureteral obstruction and aortic constriction in the Munich-Wistar rat kidney. Naunyn Schmiedebergs Arch Pharmacol 1981; 317: 86-89.
16. Cantley LG, Spokes K, Clark B et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 44: 1217-1223.
17. Heyman SN, Brezis M, Reubinoff CA et al. Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988; 82: 401-412.
18. Heyman SN, Brezis M, Epstein FH et al. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991; 40: 632-642.
19. Dzgoeva FU, Milovanov I, Kutyrina IM. Acute kidney failure related to the use of X-ray contrast agents and indomethacin: the risk factors and mechanisms of its development]. Ter Arkh 1995; 67: 36-39.
20. Carvallo A, Rakowski TA, Argy Jr WP, Schreiner GE. Acute renal failure following drip infusion pyelography. Am J Med 1978; 65: 38-45.
21. Weisbord SD, Bruns FJ, Saul MI, Palevsky PM. Provider use of preventive strategies for radiocontrast nephropathy in high-risk patients. Nephron Clin Pract 2004; 96: c56-c62.
22. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496.
23. Swan SK, Rudy DW, Lasseter KC et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.
24. Segal R, Lubart E, Leibovitz A et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med 2003; 115: 462-466.
25. Kurnik BR, Weisberg LS, Cuttler IM, Kurnik PB. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med 1990; 116: 27-36.
26. Kurnik BR, Allgren RL, Genter FC et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31: 674-680.
27. Oldroyd S, Slee SJ, Haylor J et al. Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci Colch 1994; 87: 427-434.
28. Wang A, Holcslaw T, Bashore TM et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-1680.
29. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261.
30. Toprak O, Cirit M, Bayata S et al. The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg 2003; 3: 98-103.
31. Gupta RK, Kapoor A, Tewari S et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51: 521-526.
32. Katholi RE, Taylor GJ, McCann WP et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195: 17-22.
33. Arend LJ, Bakris GL, Burnett JCJ et al. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987; 110: 406-411.
34. Bellomo R, Chapman M, Finfer S et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet 2000; 356: 2139-2143.
35. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-524.
36. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1996; 101: 49-53.
37. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291.
38. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-415.
39. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-1420.
40. Stevens MA, McCullough PA, Tobin KJ et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999; 33: 403-411.
41. Cantarovich F, Rangoonwala B, Lorenz H et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44: 402-409.
42. Shilliday I, Quinn K, Allison M. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dialysis Transplant 1997; 12: 2592-2596.
43. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
44. Moore RD, Smith CR, Lipsky JJ et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352-357.
45. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
46. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-334.
47. Butler WT, Bennett JE, Alling DW et al. Nephrotoxicity of amphotericin B; early and late effects in 81 patients. Ann Intern Med 1964; 61: 175-187.
48. Miralbell R, Sancho G, Bieri S et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys 2004; 58: 809-816.
49. McDougal WS. Early detection of acute renal failure by serum cystatin C. J Urol 2005; 174: 1024-1025.
50. Larsson A, Helmersson J, Hansson LO, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005; 65: 301-305.
51. Herget-Rosenthal S, Pietruck F, Volbracht L et al. Serum cystatin C - a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol 2005; 64: 41-46.
52. Grubb A, Bjork J, Lindstrom V et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005; 65: 153-162.
53. Larsson A, Cystatin C. an emerging glomerular filtration rate marker. Scand J Clin Lab Invest 2005; 65: 89-91.
54. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews Art. No.: CD002967. Doi: 10.1002/14651858.CD002967.[3]. 2003.
55. Paiva H, Thelen KM, Van Coster R et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60-68.
56. Al Shohaib S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. Am J Nephrol 2000; 20: 212-213.
57. Moro H, Tsukada H, Tanuma A et al. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS 2004; 18: 687-690.
58. Khanal S, Attallah N, Smith DE et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
59. Attallah N, Yassine L, Musial J et al. The potential role of statins in contrast nephropathy. Clin Nephrol 2004; 62: 273-278.
60. Gueler F, Rong S, Park JK et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13: 2288-2298.